October 2024

World Vaccine Congress: TNX-801 MPOX — A live, attenuated, minimally replicative, MPOX vaccine candidate

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: The Importance of in Vitro Discriminatory Tests in the Development of a Sublingual Dosage Form of TNX-102 SL (Cyclobenzaprine HCI) Tablets

September 2024

Pharmaceutics and Novel Drug Delivery Systems (PDDS) Conference 2024: Pharmacokinetic Properties of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine Hydrochloride

September 2024

Symposium to Honor Prof. David Evans: Using Synthetic Biology to Battle Mpox

August 2024

MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing

August 2024

MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD

August 2024

MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL

August 2024

MHSRS 2024: TNX-102 SL for Fibromyalgia

August 2024

IASP 2024: Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase 3 RESILIENT Trial Consistent with Syndromal Improvement

June 2024

Vaccine Congress 2024: Horsepox: A Live Virus, Single-Dose Vaccine Platform